Table of Contents
India Launches First CAR T-Cell Therapy, Qartemi, for Non-Hodgkin’s Lymphoma
- Immuneel Therapeutics has introduced Qartemi, India’s first global CAR T-cell therapy.
- The therapy is designed for adult B-cell Non-Hodgkin’s Lymphoma (B-NHL) patients.
- It marks a significant advancement in cancer treatment within India.
- Qartemi is a personalized therapy offering renewed hope for patients.
- It targets individuals who have not responded to traditional treatments like chemotherapy.
Rising Burden of Blood Cancers in India
- Blood Cancer Cases: Around 120,000 new cases annually
- Annual Deaths: Over 70,000 deaths from blood cancers
- Main Conditions: Includes leukemia, lymphoma, and multiple myeloma
- Non-Hodgkin’s Lymphoma: Affects 40,000 new patients each year
- Urgent Need: Necessity for advanced treatment options
Introduction of Qartemi: A Personalized Therapy
- Genetically Modified T-Cells: Utilizes engineered T-cells to target cancer.
- India’s Immunotherapy Milestone: Marks a transformative step in cancer treatment.
- Global Standards: Benchmarked to international practices.
- Local Availability: Now accessible within India.
- Renewed Hope: Offers options for patients unresponsive to traditional treatments.
Leadership and Vision
- Company Mission: Affordable cancer therapies
- Focus on Innovation: Lifesaving treatments
- Qartemi’s Goal: Transform cancer care
- Personalized Approach: Advanced, tailored therapies
- Affordable Access: Cost-effective solutions
Clinical Trials and Efficacy
- IMAGINE Trial: Initiated India’s first CAR T-cell therapy trial in 2022.
- Trial Locations: Conducted at Narayana Hospital (Bengaluru), Apollo Cancer Hospital (Chennai), and PGIMER (Chandigarh).
- Therapy Name: Therapy named “Qartemi.”
- Comparable Efficacy: Efficacy and safety comparable to US FDA-approved CAR T-cell therapies.
- Phase 2 Results: Achieved 83.3% Overall Response Rate (ORR) at Day 90.
- New Benchmark: Set a milestone for CAR T-cell therapy in India.
Strategic Partnerships for Accessibility
- Hospital Collaborations: Partnered with leading hospitals across India.
- Narayana Health: Collaboration for advanced treatment delivery.
- Apollo Hospitals: Partnership to enhance care experience.
- CMC Vellore & Ludhiana: Integrated into their care network.
- Manipal Hospitals: Streamlining treatment accessibility.
- RGCIRC Delhi: Partnered to improve cancer care.
- SGPGI Lucknow: Advanced treatment integration.
- Amrita Faridabad: Collaborating for better healthcare.
- HOC Vedanta Ahmedabad: Supporting streamlined delivery.
- Cytecare Bangalore: Enhancing patient care.
- Sparsh Bangalore: Strengthening treatment delivery.
- Marengo Asia Hospitals: Broadening healthcare accessibility.
- Stakeholder Benefits: Improved care experience for all.
Affordability and Indigenous Development
- Cost Range: ₹35-50 lakhs
- Affordable Option: Cheaper than global therapies
- Patient Access: Ensures affordability for Indian patients
- Quality Assurance: Maintains high global standards
- Indigenous Development: Produced at Bangalore facility
- Safety & Efficacy: Adheres to international standards
A New Era in Cancer Treatment
- Pivotal Moment: Launch of Qartemi marks a significant step in India’s cancer fight.
- Precision Therapy: Introduction of personalized CAR T-cell therapy.
- Global Standards: Therapy meets international benchmarks.
- Breakthrough Treatment: Immuneel Therapeutics brings innovative therapy to India.
- Access & Hope: Improved healthcare access and hope for Indian families.
- Aligned Mission: Supports India’s broader cancer combat efforts.
Important questions
- What is Qartemi and what type of cancer does it target?
- How does Qartemi differ from traditional cancer treatments like chemotherapy?
- What were the results of the IMAGINE Trial for Qartemi’s efficacy?
- How is Qartemi made affordable for Indian patients despite being a global therapy?
- Which hospitals and institutions are collaborating to provide Qartemi in India?
Conclusion
The launch of Qartemi, India’s first CAR T-cell therapy for B-cell Non-Hodgkin’s Lymphoma, marks a revolutionary step in cancer treatment, offering personalized, advanced, and cost-effective options for patients, particularly those unresponsive to conventional therapies. With significant clinical trial results and strategic hospital partnerships, Qartemi holds the promise of transforming cancer care in India, providing renewed hope for patients and addressing the growing burden of blood cancers.
Download Online Mock Test Mobile APP
3
